Early MRD-positivity in NPM-ALK positive anaplastic large cell lymphoma correlates with a very high relapse risk and inferior survival.
Introduction
The relapse rate of children with anaplastic large cell lymphoma (ALCL) reaches 25-35% with current chemotherapy [1] [2] [3] [4] . More than 95% of childhood ALCL express anaplastic lymphoma kinase (ALK) fusion proteins, 90% of which carry the translocation t(2;5)(p23;q35) resulting in the specific fusion gene Nucleophosmin (NPM)-ALK 5;6 . NPM-ALK-expressing cells can be detected in bone marrow (BM) or blood (PB) by RT-PCR in 50-60% of patients with NPM-ALK positive ALCL as a sign of minimal disseminated disease (MDD) 7;8 . MDD turned out to be a significant prognostic factor 7-9 in addition to the histological subtype and clinical risk factors 10;11 .
In vivo response to chemotherapy measured by minimal residual disease (MRD) has been established as the strongest prognostic factor for children with acute lymphoblastic leukemia [12] [13] [14] . In Burkitt´s leukemia, early detection of MRD could identify patients at highest risk of relapse as well 15 .
We, therefore, investigated whether detection of minimal residual disease (MRD) by qualitative RT-PCR for NPM-ALK in MDD-positive patients in BM or PB early during treatment allows identification of patients at highest risk of relapse in ALCL. 
Qualitative PCR for NPM-ALK
Total RNA was isolated from mononuclear or nuclear BM or PB samples by standard methods. cDNA synthesis was performed using 1µg total RNA, random hexamers and superscript II reverse transcriptase (Invitrogen, Carlsbad,CA, USA). The qualitative PCR with a sensitivity of 10 -5 was performed as previously described [7] [8] [9] .
Statistical analysis
Analysis of event-free survival (EFS) and overall survival (OS) was performed using the Kaplan-Meier method with differences compared by the log-rank test. Cumulative incidence functions for relapse were constructed following the method of Kalbfleisch and Prentice 18 . Functions were compared with Gray's test 19 .
The prognostic effect of MRD on treatment outcome was compared with other known prognostic factors in patients with ALCL using Cox regression analysis 20 . All analyses were performed using SAS (SAS-PC, version 9.1, Cary, NC: SAS Institute Inc.). Data were updated as of June 2012.
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Results and Discussion
Five-year OS and EFS for the whole group of 180 patients with MDD measurement were 84±3% and 65±4%, respectively. The cumulative incidence of relapse (CIR) was 32±4%. As in our previous report with a limited patient number 8 , MDD in BM and PB was highly concordant (data not shown). Therefore, both media were accepted for MDD-and MRD-assessment.
Minimal disseminated disease (MDD)
MDD was detected in BM, PB or both in 103 of 180 patients (57%) with NPM-ALK positive ALCL, which was comparable to our earlier reports 7-9 . MDD-positivity significantly correlated with mediastinal or visceral involvement, stage and histological subtype (supplementary table S1) confirming our earlier observations in a large patient cohort [7] [8] [9] .
46 of 103 MDD-positive patients relapsed compared to 10 of 77 patients without detectable MDD (CIR 46±5% versus 15±5%, P<.001). MDD-positive patients had a 5-year EFS and OS of 51±5% and 79±4%, respectively, compared to 83±5% and 91±3%, respectively, for MDD-negative patients (P <.0001 for EFS and .016 for OS).
Minimal residual disease (MRD)
PB and/or BM before the second course of chemotherapy were available for MRDmeasurement from 52 of 103 patients with detectable MDD. 26 were MRD-positive and 26 MRD-negative. MRD-positivity among MDD-positive patients significantly correlated with non-common histological subtype but not with clinical characteristics (Table 1) .
For control purposes we measured MRD from 23 MDD-negative patients. None of these patients turned MRD-positive.
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